Concepts and clinical use of ultra-long basal insulin

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

(2014) Matthew C. Riddle et al.   DIABETES CARE

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)

(2014) Hannele Yki-Järvinen et al.   DIABETES CARE

The Impact of Nocturnal Hypoglycemia on Clinical and Cost-Related Issues in Patients With Type 1 and Type 2 Diabetes

(2014) Steven V. Edelman et al.   DIABETES EDUCATOR

Impact of hypoglycemia on patients with type 2 diabetes mellitus and their quality of life, work productivity, and medication adherence

(2014) Janice Lopez et al.   Patient Preference and Adherence

Are Metabolically Healthy Overweight and Obesity Benign Conditions?

(2013) Caroline K. Kramer et al.   ANNALS OF INTERNAL MEDICINE

The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes

(2013) L. Meneghini et al.   DIABETES CARE

Standards of Medical Care in Diabetes--2014

(2013)   DIABETES CARE

A nine country study of the burden of non-severe nocturnal hypoglycaemic events on diabetes management and daily function

(2013) M. Brod et al.   DIABETES OBESITY & METABOLISM

Basal insulin analogues in the management of diabetes mellitus: what progress have we made?

(2013) David R. Owens et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial

(2013) H. W. Rodbard et al.   DIABETIC MEDICINE

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN®Basal-Bolus Type 1): 2-year results of a randomized clinical trial

(2013) B. W. Bode et al.   DIABETIC MEDICINE

Real-world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review

(2013) M. J. Davies et al.   DIABETIC MEDICINE

Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries

(2013) Marc Evans et al.   Health and Quality of Life Outcomes

Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension

(2013) Chantal Mathieu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Evolution of Insulin Development: Focus on Key Parameters

(2012) Joseph M. Tibaldi   ADVANCES IN THERAPY

Initiating insulin in patients with type 2 diabetes

(2012) A. N. C. Lau et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study

(2012) J. Rosenstock et al.   DIABETES CARE

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes

(2012) R. M. Bergenstal et al.   DIABETES CARE

Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)

(2012) B. Zinman et al.   DIABETES CARE

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

(2012) R. E. Ratner et al.   DIABETES OBESITY & METABOLISM

Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

(2012) M. Peyrot et al.   DIABETIC MEDICINE

The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients

(2012) Setareh A. Williams et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

(2012) Alan J Garber et al.   LANCET

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

(2012) Simon Heller et al.   LANCET

Uncovering undetected hypoglycemic events

(2012) Jeffrey Unger   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

The Impact of Non-Severe Hypoglycemic Events on Work Productivity and Diabetes Management

(2011) Meryl Brod et al.   VALUE IN HEALTH

How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes

(2010) S. Arnolds et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Hypoglycemic Episodes and Risk of Dementia in Older Patients With Type 2 Diabetes Mellitus

(2009) Rachel A. Whitmer   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Utility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the United Kingdom

(2008) Adrian R Levy et al.   Health and Quality of Life Outcomes